Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Léna Royston, Stavroula Masouridi‐Levrat, Verena Gotta, Eva Royston, Caroline Pressacco-Brossier, Yasmine Abi Aad, David Tonoli, Abderrahim Karmime, Murielle Jayo, Christian van Delden, Pierre Lescuyer, Marc Pfister, Yves Chalandon, Dionysios Neofytos
Abstract
, without noticeable associations with clinical efficacy. Letermovir exposure was not affected by gastrointestinal symptoms, but with posaconazole and cyclosporine administration. Associations between letermovir and concomitantly administered agents and adverse events warrant additional clinical studies.
Topics & Concepts
MedicineInternal medicineTherapeutic drug monitoringHematopoietic stem cell transplantationPosaconazoleOdds ratioGastroenterologyAdverse effectConfidence intervalTransplantationPharmacokineticsDermatologyAmphotericin BAntifungalCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsPolyomavirus and related diseases